莫沙必利对比质子泵抑制剂治疗功能性消化不良疗效与安全性的系统评价

发布时间：2018-04-05 05:05

  本文选题：莫沙必利　切入点：质子泵抑制剂　出处：《中国药房》2015年15期

【摘要】：目的:系统评价莫沙必利对比质子泵抑制剂(PPI)治疗功能性消化不良(FD)的疗效和安全性,以为临床治疗提供循证参考。方法:计算机检索Pub Med、EMBase、Medline、Cochrane图书馆、相关期刊论文、万方数据库,纳入莫沙必利(试验组)对比PPI(对照组)治疗FD的随机对照试验(RCT),提取资料并评价质量后,采用Rev Man 5.2统计软件进行Meta分析。结果:共纳入12项RCT,合计1 750例患者。Meta分析结果显示,试验组患者总缓解率[OR=0.56,95%CI(0.45,0.70),P0.000]、反酸缓解率[MD=0.63,95%CI(0.50,0.75),P0.000]、腹痛缓解率[MD=0.65,95%CI(0.57,0.80),P0.000]均显著低于对照组,而腹胀缓解率[MD=-0.01,95%CI(-0.18,0.16),P=0.91]、不良反应发生率[OR=1.83,95%CI(0.73,4.59),P=0.19]与对照组比较差异无统计学意义。结论:PPI治疗FD的疗效优于莫沙必利,安全性相当。由于受纳入研究样本量的限制及文献质量的影响,该结论有待大样本、高质量的RCT进一步验证。
[Abstract]:Objective: to evaluate the efficacy and safety of mosapride compared with proton pump inhibitor (PPI) in the treatment of functional dyspepsia (FDD).Methods: a computerized search was conducted for the Pub Medline Medline of Cochrane Library, full text Database of Chinese Journals, Wanfang Database, and mosapride (trial group), compared with Pub (control group) in a randomized controlled trial of FD treatment. The data were extracted and the quality was evaluated.Meta analysis was carried out with Rev Man 5.2 statistical software.缁撴灉:鍏辩撼鍏，

本文编号：1713308